Biology of Blood and Marrow Transplantation
Volume 12, Issue 1 , Pages 61-67 , January 2006

High Disease Burden Is Associated with Poor Outcomes for Patients with Acute Myeloid Leukemia Not in Remission Who Undergo Unrelated Donor Cell Transplantation

  • William Blum

      Affiliations

    • Division of Hematology and Oncology, The Ohio State University Hospitals, Columbus, Ohio
    • Corresponding Author InformationCorrespondence and reprint requests: William Blum, MD, Division of Hematology and Oncology and Comprehensive Cancer Center, The Ohio State University, B310 Starling-Loving Hall, 320 W. 10th Ave., Columbus, OH 43210.
    • ,
  • Brian J. Bolwell

      Affiliations

    • Division of Hematology and Oncology, The Cleveland Clinic, Cleveland, Ohio
    • ,
  • Gary Phillips

      Affiliations

    • Department of Biostatistics, The Ohio State University Hospitals, Columbus, Ohio
    • ,
  • Sherif S. Farag

      Affiliations

    • Division of Hematology and Oncology, The Ohio State University Hospitals, Columbus, Ohio
    • ,
  • Thomas S. Lin

      Affiliations

    • Division of Hematology and Oncology, The Ohio State University Hospitals, Columbus, Ohio
    • ,
  • Belinda R. Avalos

      Affiliations

    • Division of Hematology and Oncology, The Ohio State University Hospitals, Columbus, Ohio
    • ,
  • Sam L. Penza

      Affiliations

    • Division of Hematology and Oncology, The Ohio State University Hospitals, Columbus, Ohio
    • ,
  • Guido Marcucci

      Affiliations

    • Division of Hematology and Oncology, The Ohio State University Hospitals, Columbus, Ohio
    • ,
  • John C. Byrd

      Affiliations

    • Division of Hematology and Oncology, The Ohio State University Hospitals, Columbus, Ohio
    • ,
  • Matt E. Kalaycio

      Affiliations

    • Division of Hematology and Oncology, The Cleveland Clinic, Cleveland, Ohio
    • ,
  • Ronald M. Sobecks

      Affiliations

    • Division of Hematology and Oncology, The Cleveland Clinic, Cleveland, Ohio
    • ,
  • Brad Pohlman

      Affiliations

    • Division of Hematology and Oncology, The Cleveland Clinic, Cleveland, Ohio
    • ,
  • Stacey Brown

      Affiliations

    • Division of Hematology and Oncology, The Cleveland Clinic, Cleveland, Ohio
    • ,
  • Patrick J. Elder

      Affiliations

    • Division of Hematology and Oncology, The Ohio State University Hospitals, Columbus, Ohio
    • ,
  • Edward A. Copelan

      Affiliations

    • Division of Hematology and Oncology, The Ohio State University Hospitals, Columbus, Ohio

Received 12 January 2005 ,Accepted 27 June 2005.

References 

  1. Biggs JC , Horowitz MM , Gale RP , et al.   Bone marrow transplants may cure patients with acute leukemia never achieving remission with chemotherapy . Blood . 1992;80:1090–1093
  2. Mehta J , Powles R , Horton C , et al.   Bone marrow transplantation for primary refractory acute leukaemia . Bone Marrow Transplant . 1994;14:415–418
  3. Geller RB , Saral R , Piantadosi S , et al.   Allogeneic bone marrow transplantation after high-dose busulfan and cyclophosphamide in patients with acute nonlymphocytic leukemia . Blood . 1989;73:2209–2218
  4. Michallet M , Thomas X , Vernant JP , et al.   Long-term outcome after allogeneic hematopoietic stem cell transplantation for advanced stage acute myeloblastic leukemia (a retrospective study of 379 patients reported to the Societe Francaise de Greffe de Moelle (SFGM)) . Bone Marrow Transplant . 2000;26:1157–1163
  5. Sierra J , Storer B , Hansen JA , et al.   Unrelated donor marrow transplantation for acute myeloid leukemia (an update of the Seattle experience) . Bone Marrow Transplant . 2000;26:397–404
  6. Hallemeier C , Girgis M , Blum W , et al.   Outcomes of adults with acute myelogenous leukemia in remission given 550 cGy of single-exposure total body irradiation, cyclophosphamide, and unrelated donor bone marrow transplants . Biol Blood Marrow Transplant . 2004;10:310–319
  7. Copelan EA , Biggs JC , Thompson JM , et al.   Treatment for acute myelocytic leukemia with allogeneic bone marrow transplantation following preparation with BuCy2 . Blood . 1991;78:838–843
  8. Basara N , Baurmann H , Kolbe K , et al.   Antithymocyte globulin for the prevention of graft-versus-host disease after unrelated hematopoietic stem cell transplantation for acute myeloid leukemia (results from the multicenter German cooperative study group) . Bone Marrow Transplant . 2005;35:1011–1018
  9. Fung HC , Stein A , Slovak M , et al.   A long-term follow-up report on allogeneic stem cell transplantation for patients with primary refractory acute myelogenous leukemia (impact of cytogenetic characteristics on transplantation outcome) . Biol Blood Marrow Transplant . 2003;9:766–771
  10. Kalaycio M , Rybicki L , Pohlman B , et al.   CD8+ T-cell-depleted, matched unrelated donor, allogeneic bone marrow transplantation for advanced AML using busulfan-based preparative regimens . Bone Marrow Transplant . 2005;35:247–252
  11. Glucksberg H , Storb R , Fefer A , et al.   Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors . Transplantation . 1974;18:295–304
  12. Shulman HM , Sale GE , Lerner KG , et al.   Chronic cutaneous graft-versus-host disease in man . Am J Pathol . 1978;91:545–570
  13. Byrd JC , Mrozek K , Dodge RK , et al.   Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia (results from Cancer and Leukemia Group B (CALGB 8461)) . Blood . 2002;100:4325–4336
  14. Girgis M , Hallemeier C , Blum W , et al.   Chimerism and clinical outcomes of 110 unrelated donor bone marrow transplant recipients conditioned with low dose (550 cGy), single exposure total body irradiation and cyclophosphamide . Blood. . 2004;105:3035–3041
  15. Clift RA , Buckner CD , Appelbaum FR , et al.   Allogeneic marrow transplantation during untreated first relapse of acute myeloid leukemia . J Clin Oncol . 1992;10:1723–1729
  16. Godder KT , Mehta J , Chiang KY , et al.   Partially mismatched related donor bone marrow transplantation as salvage for patients with AML who failed autologous stem cell transplant . Bone Marrow Transplant . 2001;28:1031–1036
  17. Maris MB , Niederwieser D , Sandmaier BM , et al.   HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies . Blood . 2003;102:2021–2030
  18. Sayer HG , Kroger M , Beyer J , et al.   Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia (disease status by marrow blasts is the strongest prognostic factor) . Bone Marrow Transplant . 2003;31:1089–1095
  19. Mehta J , Powles R , Treleaven J , Kulkarni S , Horton C , Singhal S . Number of nucleated cells infused during allogeneic and autologous bone marrow transplantation (an important modifiable factor influencing outcome) . Blood . 1997;90:3808–3810
  20. Singhal S , Powles R , Treleaven J , et al.   A low CD34+ cell dose results in higher mortality and poorer survival after blood or marrow stem cell transplantation from HLA-identical siblings (should 2 × 106 CD34+ cells/kg be considered the minimum threshold?) . Bone Marrow Transplant . 2000;26:489–496
  21. Dominietto A , Lamparelli T , Raiola AM , et al.   Transplant-related mortality and long-term graft function are significantly influenced by cell dose in patients undergoing allogeneic marrow transplantation . Blood . 2002;100:3930–3934

PII: S1083-8791(05)00424-6

doi: 10.1016/j.bbmt.2005.06.004

Biology of Blood and Marrow Transplantation
Volume 12, Issue 1 , Pages 61-67 , January 2006

Article Tools

* Image Usage & Resolution